Compare with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES STRIDES PHARMA SCIENCE ALKEM LABORATORIES/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 24.4 22.0 111.1% View Chart
P/BV x 5.9 2.1 285.8% View Chart
Dividend Yield % 0.8 0.2 349.3%  

Financials

 ALKEM LABORATORIES   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
STRIDES PHARMA SCIENCE
Mar-18
ALKEM LABORATORIES/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs2,7201,147 237.1%   
Low Rs1,660642 258.6%   
Sales per share (Unadj.) Rs697.9317.2 220.0%  
Earnings per share (Unadj.) Rs96.17.8 1,225.3%  
Cash flow per share (Unadj.) Rs117.325.1 468.0%  
Dividends per share (Unadj.) Rs25.002.00 1,250.0%  
Dividend yield (eoy) %1.10.2 510.5%  
Book value per share (Unadj.) Rs515.2274.3 187.9%  
Shares outstanding (eoy) m119.5789.50 133.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.12.8 111.3%   
Avg P/E ratio x22.8114.0 20.0%  
P/CF ratio (eoy) x18.735.7 52.3%  
Price / Book Value ratio x4.33.3 130.3%  
Dividend payout %26.025.5 102.0%   
Avg Mkt Cap Rs m261,87980,058 327.1%   
No. of employees `00014.32.5 571.6%   
Total wages/salary Rs m15,0554,341 346.8%   
Avg. sales/employee Rs Th5,822.611,325.8 51.4%   
Avg. wages/employee Rs Th1,050.51,731.4 60.7%   
Avg. net profit/employee Rs Th802.0280.1 286.4%   
INCOME DATA
Net Sales Rs m83,44428,394 293.9%  
Other income Rs m1,042941 110.8%   
Total revenues Rs m84,48629,334 288.0%   
Gross profit Rs m14,7343,965 371.6%  
Depreciation Rs m2,5281,540 164.1%   
Interest Rs m6511,962 33.2%   
Profit before tax Rs m12,5981,403 897.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1,10597 1,135.5%   
Profit after tax Rs m11,493702 1,637.0%  
Gross profit margin %17.714.0 126.4%  
Effective tax rate %8.86.9 126.5%   
Net profit margin %13.82.5 557.0%  
BALANCE SHEET DATA
Current assets Rs m54,96024,836 221.3%   
Current liabilities Rs m32,43318,993 170.8%   
Net working cap to sales %27.020.6 131.2%  
Current ratio x1.71.3 129.6%  
Inventory Days Days8071 112.1%  
Debtors Days Days72113 63.6%  
Net fixed assets Rs m32,71034,289 95.4%   
Share capital Rs m239895 26.7%   
"Free" reserves Rs m61,36823,651 259.5%   
Net worth Rs m61,60724,546 251.0%   
Long term debt Rs m1,59215,513 10.3%   
Total assets Rs m99,43365,437 152.0%  
Interest coverage x20.41.7 1,187.3%   
Debt to equity ratio x00.6 4.1%  
Sales to assets ratio x0.80.4 193.4%   
Return on assets %12.24.1 299.9%  
Return on equity %18.72.9 652.2%  
Return on capital %21.06.9 304.1%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06115,697 102.3%   
Fx outflow Rs m2,483735 337.6%   
Net fx Rs m13,57814,962 90.8%   
CASH FLOW
From Operations Rs m5,8511,871 312.8%  
From Investments Rs m-7,4145,826 -127.3%  
From Financial Activity Rs m792-10,157 -7.8%  
Net Cashflow Rs m-731-2,615 28.0%  

Share Holding

Indian Promoters % 66.9 27.7 241.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 37.8 87.6%  
FIIs % 0.0 8.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 25.9 -  
Shareholders   68,381 56,241 121.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 22, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - NEULAND LABS COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS